Last reviewed · How we verify
Aliskiren/HCTZ
Aliskiren/HCTZ is a fixed-dose combination that lowers blood pressure by blocking the renin-angiotensin system and promoting sodium and water excretion.
Aliskiren/HCTZ is a fixed-dose combination that lowers blood pressure by blocking the renin-angiotensin system and promoting sodium and water excretion. Used for Hypertension.
At a glance
| Generic name | Aliskiren/HCTZ |
|---|---|
| Sponsor | Novartis |
| Drug class | Direct renin inhibitor / thiazide diuretic combination |
| Target | Renin; sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Aliskiren is a direct renin inhibitor that blocks the first step of the renin-angiotensin-aldosterone system (RAAS), preventing the conversion of angiotensinogen to angiotensin I. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that reduces blood volume by increasing urinary sodium and water excretion. Together, they provide complementary antihypertensive effects.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Hypokalemia
- Cough
- Headache
Key clinical trials
- A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension (PHASE3)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension (PHASE4)
- Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension (PHASE4)
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients (PHASE3)
- Aldosterone and the Metabolic Syndrome (PHASE1)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren/HCTZ CI brief — competitive landscape report
- Aliskiren/HCTZ updates RSS · CI watch RSS
- Novartis portfolio CI